DusanStefoskiMD

PubMed

• Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case report.
  Konrad Kubicki, Dusan Stefoski> ;Multiple Sclerosis. 2024 Mar 8
• A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
  Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Xavier Montalban, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Ayde...> ;Neurodegenerative Disease Management. 2023 Oct 1
• Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders.
  Allison Osen, Dusan Stefoski, Thomas Shoemaker, Tyler Kaplan, Fabian Sierra Morales> ;Journal of the Neurological Sciences. 2023 Aug 15
• 4 citations
  Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
  Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Xavier Montalban, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Ayde...> ;Multiple Sclerosis. 2023 May 1
• The rare case of a 20-year-old male with rapidly progressive primary angiitis of the CNS with a good outcome.
  Edith Graham, Thomas Shoemaker, Dusan Stefoski, Marinos Kontzialis, Anam Naumaan, Rajeev K. Garg> ;Neurology(R) Neuroimmunology & Neuroinflammation. 2020 Jun 9
• 7 citations
  Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
  Ralf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, Krzysztof Selmaj, Eva Havrdova, Xavier Montalban, Dusan Stefoski, Till Sprenger, Randy Robinson, Sami Fam, Jonathan S...> ;Journal of Neurology. 2020 May 25
• 14 citations
  Treatment of natalizumab-associated PML with filgrastim.
  Dusan Stefoski, Roumen Balabanov, Rasha Waheed, Michael Ko, Igor J. Koralnik, Fabian Sierra Morales> ;Annals of Clinical and Translational Neurology. 2019 Apr 8
• 7 citations
  Glioblastoma in natalizumab‐treated multiple sclerosis patients
  Fabian Sierra Morales, Robert B. Wright, Jorge Novo, Leonidas D. Arvanitis, Dusan Stefoski, Igor J. Koralnik> ;Annals of Clinical and Translational Neurology. 2017 Jun 6
• 36 citations
  Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
  Ralf Gold, Ernst-Wilhelm Radue, Gavin Giovannoni, Krzysztof Selmaj, Eva Havrdova, Dusan Stefoski, Till Sprenger, Xavier Montalban, Stanley Cohan, Kimberly Umans, Steve...> ;BMC Neurology. 2016 Jul 26
• 13 citations
  Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.
  Ralf Gold, Dusan Stefoski, Krzysztof Selmaj, Eva Havrdova, Christopher Hurst, Joan Holman, Belen Tornesi, Surekha Akella, Peter McCroskery> ;Neurology and Therapy. 2016 Jul 13
• 8 citations
  Daclizumab high‐yield process reduced the evolution of new gadolinium‐enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis
  E. W. Radue, Till Sprenger, Timothy Vollmer, Gavin Giovannoni, R. Gold, Eva Havrdova, Krzysztof Selmaj, Dusan Stefoski, Xiaojun You, Jacob Elkins> ;European Journal of Neurology. 2016 Feb 1
• 7 citations
  Is cervical decompression beneficial in patients with coexistent cervical stenosis and multiple sclerosis
  Lee A. Tan, Manish K. Kasliwal, Christopher C. Muth, Dusan Stefoski, Vincent C. Traynelis> ;Journal of Clinical Neuroscience. 2014 Dec 1
• 44 citations
  Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum.
  Yong Guo, Vanda A. Lennon, Bogdan F. Gh. Popescu, Carrie Grouse, Jordan L. Topel, Margherita Milone, Hans Lassmann, Joseph E. Parisi, Sean J. Pittock, Dusan Stefoski, ...> ;JAMA Neurology. 2014 Aug 1
• 23 citations
  Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
  Eva Havrdova, Gavin Giovannoni, Dusan Stefoski, Samantha Forster, Kimberly Umans, Lahar Mehta, Steven Greenberg, Jacob Elkins> ;Multiple Sclerosis. 2014 Apr 1
• 74 citations
  Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
  Gavin Giovannoni, Ralf Gold, Krzysztof Selmaj, Eva Havrdova, Xavier Montalban, Ernst-Wilhelm Radue, Dusan Stefoski, Manjit McNeill, Lakshmi Amaravadi, Marianne T. Swee...> ;The Lancet. Neurology. 2014 May 1
• 224 citations
  Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
  Ralf Gold, Gavin Giovannoni, Krzysztof Selmaj, Eva Havrdova, Xavier Montalban, Ernst-Wilhelm Radue, Dusan Stefoski, Randy Robinson, Katherine Riester, Jitesh Rana, Jac...> ;Lancet. 2013 Jun 22
• 27 citations
  Cross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis Optica
  Zhihua Ren, Yan Wang, Tao Duan, Jilpa Patel, Thomas Liggett, Eileah Loda, Sarang Brahma, Rajendra Goswami, Carrie Grouse, Richard W. Byrne, Dusan Stefoski, Adil Javed,...> ;Journal of Immunology. 2012 Nov 1
• 24 citations
  Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis
  Zhihua Ren, Yan Wang, Duan Tao, David Liebenson, Thomas Liggett, Rajendra Goswami, Robert Clarke, Dusan Stefoski, Roumen Balabanov> ;The Journal of Neuroscience. 2011 Jun 8
• 19 citations
  IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination.
  Zhihua Ren, Yan Wang, David Liebenson, Thomas Liggett, Rajendra Goswami, Dusan Stefoski, Roumen Balabanov> ;Journal of Neuroimmunology. 2011 Apr 1
• 114 citations
  Freedom from disease activity in multiple sclerosis
  Eva Havrdova, Steven Galetta, Dusan Stefoski, Giancarlo Comi> ;Neurology. 2010 Apr 27
• 7 citations
  Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis.
  Zhihua Ren, Yan Wang, Duan Tao, David Liebenson, Thomas Liggett, Rajendra Goswami, Dusan Stefoski, Roumen Balabanov> ;Journal of Neuroimmune Pharmacology. 2010 Feb 23
• 59 citations
  Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis.
  Thomas Liggett, Anatoliy A. Melnikov, Shilpa Tilwalli, Qilong Yi, Haiyan Chen, Charles Replogle, Xuan Feng, Anthony T. Reder, Dusan Stefoski, Roumen Balabanov, Victor ...> ;Journal of the Neurological Sciences. 2010 Mar 15
• 51 citations
  A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.
  Claudia C. Kaiser, Dinesh K. Shukla, Glenn T. Stebbins, Demetrios D. Skias, Douglas Jeffery, Dusan Stefoski, George Katsamakis, Douglas L. Feinstein> ;Journal of Neuroimmunology. 2009 Jun 25
• 362 citations
  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing...
  Eva Havrdova, Steven Galetta, Michael Hutchinson, Dusan Stefoski, David W. Bates, Chris H. Polman, Paul O'Connor, Gavin Giovannoni, J. Theodore Phillips, Fred D. Lubli...> ;The Lancet. Neurology. 2009 Mar 1
• 113 citations
  Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used.
  Yvonne Loh, Yu Oyama, Laisvyde Statkute, Kathleen Quigley, Kimberly Yaung, E. Gonda, Walter G. Barr, Borko Jovanovic, Robert M. Craig, Dusan Stefoski, Bruce A. Cohen, ...> ;Blood. 2007 Mar 15
• Join now to see all

Journal Articles

• Concerning the application of plasmapheresis in multiple sclerosis.  
  Schauf CL, Stefoski D, Davis FA, McLeod BC, Plasmatherapy
• Linomide in relapsing and secondary progressive MS - Trial design and clinical results.  
  Noseworthy JH, Wolinsky JS, Lublin FD et al, Neurology
• Linomide in relapsing and secondary progressive MS: MRI results.  
  Wolinsky JS, Narayana PA, Noseworthy JH et al and North American Investigators (Stefoski D int al), Neurology
• Intramuscular interferon beta 1-a therapy initiated during a first demyelinating event in multiple sclerosis.  
  Jacobs LD, Beck RW, Simon JH et al and the CHAMPS Study Group (Stefoski D int al), N Engl J Med
• Interferon beta 1-a for optic neuritis patients at high risk for multiple sclerosis.  
  Stefoski D, Am J Ophthalmol
• Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analysis.  
  Beck RW et al (Stefoski D int al), Ann Neurol
• Predictors of short-term disease activity following a first demyelinating event: Analysis if the CHAMPS placebo group.  
  CHAMPS Study Group (Stefoski D int al), Multiple Sclerosis
• MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group.  
  CHAMPS Study Group (Stefoski D int al), Neurology
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl  
  Rudick RA et al (Stefoski D int al), N Engl J Med
• The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL.  
  Calabresi PA, Giovannoni G, Confavreux C et al (Stefoski D int al), Neurology
• A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.  
  Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group (Stefoski D int..., N Engl J Med
• Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.  
  Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock..., J Neurol Sci
• Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and sub...  
  Giovannoni G, Cook S, Rammohan K, et al (Stefoski D int al), Lancet Neurol
• Join now to see all

Books/Book Chapters

• Respiratory dysfunction in neurological diseases. 
  Chapter: Central disturbances of respiration in multiple sclerosis 
  Page 203 - 220Stefoski D, Davis FAEditors: Weiner WJ.Futura NY
• Neurology for Non-Neurologists. 
  Chapter: Multiple sclerosis 
  Page 187 - 196Stefoski DEditors: Weiner WJ, Goetz C.Harper and Row, Philadelphia

Abstracts/Posters

• Correlation between diffuse EEG abnormalities and cerebral atrophy in senile dementia.
  Stefoski D, Bergen D, Fox J, Morrell F, Huckman M, Ramsey R, Gerontologist
• Plasmapheresis in multiple sclerosis: Clinical observations and effects on serum neuroelectric blocking factor.
  Stefoski D, Schauf CL, Davis FA, McLeod BC, Pencek TL, Jones JD, Haywood CP, Neurology
• Acute improvements in multiple sclerosis with intravenous mannitol, adrenocorticotropic hormone and sodium bicarbonate: A double blind study.
  Stefoski D, Davis FA, Schauf CL, Ann Neurol
• 4-Aminopyridine improves clinical signs in multiple sclerosis.
  Stefoski D, Davis FA, Faut-Tyzska M, Schauf CL, Ann Neurol
• 4-Aminopyridine administered orally improves clinical signs in multiple sclerosis.
  Davis FA, Stefoski D, Bindokas J, Schauf CL, Ann Neurol
• Testing the tongue retaining devise for control of sleep apnea.
  Cartwright R, Samelson C, Kravitz H, Stefoski D, Knight S, Caldarelli D, Sleep Research
• 4-Aminopyridine administered orally improves clinical signs in multiple sclerosis.
  Davis FA, Stefoski D, Bindokas J, Conference of the International Federation of Multiple Sclerosis Societies, Rome, Italy
• 4-Aminopyridine in multiple sclerosis: Prolonged oral administration.
  Stefoski D, Davis FA, Rush J, Fitzsimmons WE, Luskin SS, Neurology
• 4-Aminopyridine (EL-970) induced improvements in multiple sclerosis closely parallel serum levels suggesting rapid central nervous system access.
  Stefoski D, Davis FA, Rayman LH, Luskin SS, Ann Neurol
• Autologous lymphocyte depleted hematopoietic stem cell transplantation for rapidly progressive multiple sclerosis; Minimal toxicity from cyclophosphamide/total body ir...
  Burt RK, Traynor AE, Cohen B, Karlin K, Davis FA, Stefoski D, Terry C, Lobeck L, Keever-Taylor C, Burns WH, J Neurol Sci
• T-cell depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: Report on the first tree patients.
  Burt RK, Traynor AE, Cohen BA, Karlin K, Davis FA, Stefoski D, Terry C, Lobeck L, Russell J, Goolsby C, Rosen S, Gorden LI, Keever-Taylor C, Brush M, Fishman M, Burns WH, ASH 39th Annual Meeting, San Diego, CA
• T-cell depleted autologous hematopoietic stem cell transplantation for multiple sclerosis.
  Burt RK, Traynor AE, Cohen B, Karlin K, Davis FA, Stefoski D, Terry C, Lobeck L, Rowlings P, Cass T, Burns WH, American Neurological Association 123rd Annual Meeting, Montreal, Canada
• Opposite changes in IFN-[gamma] and IL-10 mRNA abundance in blood monocytes of multiple sclerosis patients following treatment with intravenous methylprednisolone.
  Quandt FN, Katsamakis G, Stefoski D, Hassen E, Sagett S, Neurology
• Cladribine effective in multiple sclerosis.
  Katsamakis G, Stefoski D, Karlin K, Davis FA, J Neurology
• Adverse effects of intravenous high dose steroid treatments.
  Katsamakis G, Stefoski D, Karlin K, Davis FA, Mult Scler
• Intense immune ablative therapy with autologous hematopoetic stem cell rescue for progressive multiple scleorsis : A pilot safety study.
  Cohen BA, Karlin KH, Lobeck L, Russell E, Davis F, Stefoski D, Burns W, Burt R, Neurology
• use of biofeedback in the treatment of ataxic dysarthria in patients with multiple sclerosis.
  Maddava K, Wang E, Stefoski D, Katsamakis G, 11th Biennial Conference on Motor Speech Disorders and Speech Motor Control, Williamsburg, VA
• White matter integrity in multiple sclerosis and its relationship to cognitive processing speed: A diffusion tensor imaging study.
  Stebbins G, Katsamakis, Carrillo MC, Stefoski D. Bangen KJ Moseley ME, Gabrieli JE, Neurology
• Decreased relapses of multiple sclerosis in patients on 4-aminopyridine.
  Stefoski D, Katsamakis G, Ko M, Mult Scler
• Immunoablation using cyclophosphamide without haematopoietic stem cell rescue for refractory multiple sclerosis.
  Ko M, Katsamakis G, Stefoski D, Shammo J, Gregory S, J Neurol, Meeting of the European Neurological Society, Vienna
• Decreased gray matter density in multiples sclerosis and its relationship to cognitive function.
  Johnson J, Katsamakis G, Stefoski D, Fleischman D, Stebbins G, Organization for Human Brain Mapping Meeting, 11th Annual Meeting, Toronto
• Cost-efficacy analysis of multiple sclerosis therapies: Assessing the impact of neutralizing antibodies.
  Munschauer F, Baker T, Dunn J, Cook R, Likosky W, Stefoski D, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 11th Annual Meeting
• Autologous non-myeloablative hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis.
  Burt RK, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Rose JW, Testori A, Muraro PA, Storek J, Voltarelli J, Multiple Sclerosis
• Natalizumab increases the proportion of disease-free patients in relapsing multiple sclerosis.
  Havrdova E, Bates D, Galetta SL, Giovannoni G, Lublin F, O'Connor P, Phillips JT, Polman C, Stefoski D, Pace A, Hyde R, Kim R, Panzara M, Multiple Sclerosis
• Immunoablation with high-dose cyclophosphamide for refractory multiple sclerosis.
  Tilwalli S, Balabanov R, Stefoski D, Katsamakis G, Ko M, Shammo J, Gregory S, Multiple Sclerosis
• Join now to see all

Lectures

• Electrophysiologic Diagnostic Criteria in Brain Death. 
  Symposium on Brain Death, Christ Hospital and Medical Center, Oak Lawn, IL
• Plasmapheresis in Multiple Sclerosis. 
  National Institute of Neurology (Queen's Square) London, GB (UK)
• Diagnosis and Management of Parkinsonism and Other Movement Disorders in the Elderly. 
  Rush Medical College and J. R. Bowman Center for the Elderly Chicago, IL
• Neurology - Occupational Orientation, Neurotoxicity and Mechanical Injuries. 
  American Occupational Medical Association, Central States Annual Meeting, Chicago, IL
• Immunology of Multiple Sclerosis. 
  Immunology - Rush Graduate College, Chicago, IL
• Symptomatic Treatment in Multiple Sclerosis. 
  34th Annual Meeting of the American Academy of Neurology Multiple Sclerosis Workshop, Washington, DC
• Treatment of Narcolepsy. 
  Sleep Disorder Symposium, Rush-Presbyterian-St. Luke's Med Center, Chicago, IL
• New Approaches to Management of Multiple Sclerosis. 
  The Wistar Institute Philadelphia, PA
• Movement Disorders in the Elderly. 
  Geriatrics Symposium, Rush-Presbyterian-St. Luke's Medical Center
• Falls and Gait Difficulties in the Elderly. 
  The Chicago Medical Society, 43rd Annual Midwest Conference, Chicago, IL
• 4-Aminopyridine in the Treatment of Multiple Sclerosis. 
  International Conference, Elan Pharmaceutical, Boston, MA, 1992
• 4-Aminopyridine in Multiple Sclerosis. 
  National Multiple Sclerosis Society Symposium Kansas City, MO
• Longitudinal Approach to Treatment of Multiple Sclerosis: Multiple Sclerosis - Challenges and Consensus. 
  Physicians World Communications Group, Chicago, IL
• Fatigue in Multiple Sclerosis. 
  Current Trends in MS. University of Texas Southwest Medical Center, Dallas, TX
• The Role of Glatiramer Acetate in the Treatment of Multiple Sclerosis. 
  International Symposium on MS. University of Ljubljana, Slovenia
• Current Concepts in Multiple Sclerosis. 
  Clinical Pharmacology Section of the Croatian Medical Society. Zagreb, Croatia
• New Concepts in Multiple Sclerosis: Cerebral Atrophy and Cognitive Deficits. 
  Neurology Grand Rounds. Sunnybrook Hospital, University of Toronto, Canada
• Management of Multiple Sclerosis. 
  National Multiple Sclerosis Society. New York Chapter St.Luke’s Roosevelt Hospital of the Columbia U
• Thinking, Memory and Attention Issues in Multiple Sclerosis. 
  National Multiple Sclerosis Society Central Pennsylvania Chapter. Harrisburg, PA
• Cognitive Issues and New Treatments in Multiple Sclerosis. 
  National Multiple Sclerosis Society Connecticut Chapters, Waterbury, CT
• Brain Parenchymal Fraction (as a Measure of CNS Atrophy in Multiple Sclerosis). 
  Universidad Internacional Menedez Pelayo, Santander, Spain
• Rationale for Early Treatment of Multiple Sclerosis. 
  University of California in San Diego. San Diego, CA
• Paradigm Shift in the Management of Multiple Sclerosis. 
  Neurology Grand Rounds. University of Illinois Medical College, Peoria, IL
• Treatment Optimization in Multiple Sclerosis. 
  Neurology Grand Round. Cedar Sinai Hospital, Los Angeles, CA
• Therapies for Breakthrough and Secondary Progressive Multiple Sclerosis. 
  Neurology Grand Rounds Columbia University. New York, NY
• Join now to see all